Clinical Observation of Employment of Umbilical Cord Derived Mesenchymal Stem Cell for Juvenile Idiopathic Arthritis TherapyReport as inadecuate

Clinical Observation of Employment of Umbilical Cord Derived Mesenchymal Stem Cell for Juvenile Idiopathic Arthritis Therapy - Download this document for free, or read online. Document in PDF available to download.

Stem Cells InternationalVolume 2016 2016, Article ID 9165267, 7 pages

Clinical Study

Cell Therapy Center, 323 Hospital of People’s Liberation Army, Xi’an 710054, China

Zhongyuan Union Cell & Gene Engineering Corporation Company, Tianjin 300304, China

Alliancells Institute of Stem Cells and Translational Regenerative Medicine & Alliancells Bioscience Co., Ltd., Tianjin 300381, China

Harold Hamm Oklahoma Diabetes Center and Section of Endocrinology and Diabetes in the Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA

Received 28 April 2015; Revised 31 July 2015; Accepted 6 August 2015

Academic Editor: Kathryn McFadden

Copyright © 2016 Liming Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Juvenile idiopathic arthritis JIA, known as Juvenile rheumatoid arthritis, is the most common type of arthritis in children aged under 17. It may cause sequelae due to lack of effective treatment. The goal of this study is to explore the therapeutic effect of umbilical cord mesenchymal stem cells UC-MSCs for JIA. Ten JIA patients were treated with UC-MSCs and received second infusion three months later. Some key values such as 28-joint disease activity score DAS28, TNF-α, IL-6, and regulatory T cells Tregs were evaluated. Data were collected at 3 months and 6 months after first treatment. DAS28 score of 10 patients was between 2.6 and 3.2 at three months after infusion. WBC, ESR, and CRP were significantly decreased while Tregs were remarkably increased and IL-6 and TNF-α were declined. Similar changes of above values were found after 6 months. At the same time, the amount of NSAIDS and steroid usage in patients was reduced. However, no significant changes were found comparing the data from 3 and 6 months. These results suggest that UC-MSCs can reduce inflammatory cytokines, improve immune network effects, adjust immune tolerance, and effectively alleviate the symptoms and they might provide a safe and novel approach for JIA treatment.

Author: Liming Wang, Yu Zhang, Hongtao Li, Jingxin Hong, Xiaobo Chen, Ming Li, Wen Bai, Jiangang Wang, Yongjun Liu, and Mingyuan



Related documents